The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 801–900 of 1,003
Gut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 29
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Self-citationIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Gasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 31
Self-citationGyldenløve, M., Vilsbøll, T., Zachariae, C. O. C., Holst, J. J., Knop, F. K., & Skov, L. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12388 · Cited by 27
Self-citationIncretin therapy for diabetes mellitus type 2
Holst, J. J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000516 · Cited by 29
Self-citationPelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 33
Interorgan Crosstalk Contributing toβ-Cell Dysfunction
Tanabe, K., Amo-Shiinoki, K., Hatanaka, M., & Tanizawa, Y. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3605178 · Cited by 30
Gastrointestinal Endocrinology
Holst, J. J., Fahrenkrug, J., STADIL, F., & Rehfeld, J. F. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609094558 · Cited by 28
Self-citationLankat–Buttgereit, B., & Göke, B. (1997) · Peptides · doi:10.1016/s0196-9781(97)00001-6 · Cited by 28
Kaneto, H., Matsuoka, T., Kimura, T., Obata, A., Shimoda, M., Kamei, S., Mune, T., & Kaku, K. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12331 · Cited by 28
Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells
Kim, H., Hong, S.-H., Oh, S.-H., Kim, J.-H., Lee, M.-S., & Lee, M. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0474 · Cited by 27
Kim, Y. G., Min, S. H., Hahn, S., Oh, T. J., Park, K. S., & Cho, Y. M. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.011 · Cited by 28
Intestinal Incretins and the Regulation of Bone Physiology
Ramsey, W. A., & Isales, C. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-66653-2_2 · Cited by 27
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 28
Exendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 28
Guccio, N., Gribble, F. M., & Reimann, F. M. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-113625 · Cited by 30
2. DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Wiedeman, P. E. (2007) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(06)45502-8 · Cited by 25
The physiology and pharmacology of incretins in type 2 diabetes mellitus
Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00920.x · Cited by 28
Self-citationYanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Atageldiyeva, K. K., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., & Haneda, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3842-y · Cited by 26
Yabe, D., Eto, T., Shiramoto, M., Irie, S., Murotani, K., Seino, Y., Kuwata, H., Kurose, T., Seino, S., Åhrén, B., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12817 · Cited by 27
Exenatide: a novel treatment of Type 2 diabetes
Åhrén, B. (2005) · Therapy · doi:10.2217/14750708.2.2.207 · Cited by 26
The Physiology of Incretin Hormones and the Basis for DPP-4 Inhibitors
McKennon, S., & Campbell, R. K. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706297451 · Cited by 27
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Gut hormones and bone homeostasis: potential therapeutic implications
Bouvard, B., & Mabilleau, G. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01000-z · Cited by 26
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists
Swedberg, J. E., Schroeder, C. I., Mitchell, J. M., Durek, T., Fairlie, D. P., Edmonds, D. J., Griffith, D. A., Ruggeri, R. B., Derksen, D. R., Loria, P. M., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.046 · Cited by 26
Trahair, L. G., Horowitz, M., Marathe, C. S., Lange, K., Standfield, S., Rayner, C. K., & Jones, K. L. (2014) · Physiological Reports · doi:10.14814/phy2.12204 · Cited by 22
Alogliptin benzoate for the treatment of type 2 diabetes
Rendell, M., Drincic, A., & Andukuri, R. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656088 · Cited by 26
Chou, W.-L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105693 · Cited by 30
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 28
Emerging GLP-1 receptor agonists
Lund, A., Knop, F. K., & Vilsbøll, T. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.616493 · Cited by 27
Mikada, A., Narita, T., Yokoyama, H., Yamashita, R., Horikawa, Y., Tsukiyama, K., & Yamada, Y. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.040 · Cited by 26
Green, B., Gault, V. A., Irwin, N., Mooney, M. H., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biological Chemistry · doi:10.1515/bc.2003.171 · Cited by 26
Gut-Derived Incretin Hormones and New Therapeutic Approaches
Bloomgarden, Z. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2554 · Cited by 26
Incretins and their role in the management of diabetes
Frías, J. P., & Edelman, S. V. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32825ea2ba · Cited by 29
Therapeutic approaches based on beta-cell mass preservation and/or regeneration
Robert, A. R. (2009) · Frontiers in bioscience · doi:10.2741/3345 · Cited by 25
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
Miyamoto, Y., Banno, Y., Yamashita, T., Fujimoto, T., Oi, S., Moritoh, Y., Asakawa, T., Kataoka, O., Takeuchi, K., Suzuki, N., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.11.038 · Cited by 25
Grespan, E., Toni Giorgino, A., Natali, A., Ferrannini, E., & Mari, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154415 · Cited by 25
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 25
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 25
Kolic, J., Spigelman, A. F., Smith, A. M., Fox, J. E. M., & MacDonald, P. E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577510 · Cited by 25
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.10.1705 · Cited by 24
Systems analysis of GLP-1 receptor signaling in pancreatic β-cells.
Takeda, Y., Amano, A., Noma, A., Nakamura, Y., Fujimoto, S., & Inagaki, N. (2011) · American Journal of Physiology - Cell Physiology · doi:10.1152/ajpcell.00057.2011 · Cited by 26
Parthsarathy, V., Hogg, C., Flatt, P. R., & O'Harte, F. P. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13068 · Cited by 25
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
Triplitt, C. L., & DeFronzo, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.3.329 · Cited by 25
Liu, G., Jacobo, S. M. P., Hilliard, N., & Hockerman, G. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097477 · Cited by 24
Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
Aulinger, B. A., Vahl, T. P., Prigeon, R. L., D'Alessio, D. A., & Elder, D. A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00496.2015 · Cited by 24
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 28
Nielsen, S. T., Lehrskov, L. L., Krogh‐Madsen, R., Solomon, T. P. J., Lehrskov, L. L., Holst, J. J., & Møller, K. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2441 · Cited by 23
Self-citationThe emerging role of the intestine in metabolic diseases
Bradley, W. D., Zwingelstein, C., & Rondinone, C. M. (2011) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2011.578651 · Cited by 24
Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Al-Zamel, N., Al‐Sabah, S., Luqmani, Y. A., Adi, L., Chacko, S., Schneider, T. D., & Krasel, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143532 · Cited by 24
Holst, J. J., Jepsen, S. L., & Modvig, I. M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102189 · Cited by 26
Self-citationNyirjesy, S. C., Peleckis, A. J., Eiel, J. N., Gallagher, K., Doliba, A., Tami, A., Flatt, A. J., León, D. D. D., Hadjiliadis, D., Sheikh, S., et al. (2022) · Diabetes · doi:10.2337/db22-0399 · Cited by 24
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 28
Christensen, M., Knop, F. K., Vilsbøll, T., Aaboe, K., Holst, J. J., Madsbad, S., & Krarup, T. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.004 · Cited by 24
Self-citationde Menthière, C. S., Chavanieu, A., Grassy, G., Dalle, S., Salazar, G., Kervran, A., Pfeiffer, B., Renard, P., Delagrange, P., Manéchez, D., et al. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.02.002 · Cited by 24
Incretin-based Therapies for Type 2 Diabetes
McIntosh, C. H. S. (2008) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(08)22010-1 · Cited by 24
Shalev, A., Ninnis, R., & Keller, U. B. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023175 · Cited by 23
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24
Shin, D., Cho, Y. M., Lee, S., Lim, K. S., Kim, J.-A., Ahn, J.-Y., Cho, J., Lee, H., Jang, I., & Yu, K. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0184-3 · Cited by 24
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 26
Tura, A., Pacini, G., Yamada, Y., Seino, Y., & Åhrén, B. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00288.2018 · Cited by 24
Doğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 27
Investigating GIPR (Ant)Agonism: A Structural Analysis of GIP and Its Receptor
Smit, F. X., van der Velden, W. J. C., Kizilkaya, H. S., Nørskov, A., Lückmann, M., Hansen, T. N., Sparre‐Ulrich, A. H., Qvortrup, K. M., Frimurer, T. M., & ROSENKILDE, M. M. (2020) · Structure · doi:10.1016/j.str.2021.04.001 · Cited by 24
Hinke, S., Pauly, R., Ehses, J. A., Kerridge, P., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650281 · Cited by 24
Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene
Boylan, M. O., Jepeal, L. I., & Wolfe, M. M. (1999) · Peptides · doi:10.1016/s0196-9781(98)00176-4 · Cited by 24
Jepeal, L. I., Boylan, M. O., & Wolfe, M. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00046-6 · Cited by 24
The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms
Nauck, M. A., & Meier, J. J. (2007) · Diabetologia · doi:10.1007/s00125-007-0832-8 · Cited by 24
Self-citationMechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 26
Yamanouchi, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010027 · Cited by 32
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
Self-citationPathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_2 · Cited by 24
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 26
The antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 24
Molecular Pharmacology of the Incretin Receptors
Al‐Sabah, S. (2015) · Medical Principles and Practice · doi:10.1159/000433437 · Cited by 22
Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells
Al‐Sabah, S., Al-Fulaij, M. A., & Ahmed, H. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.019 · Cited by 23
Patel, S., Mace, O. J., Tough, I. R., White, J. R., Cock, T., Berglund, U. W., Schindler, M., & Cox, H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.10 · Cited by 22
Moon, M. J., Kim, H. Y., Park, S., Kim, D.-K., Cho, E. B., Park, C. R., You, D., Hwang, J., Kim, K., Choe, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276808 · Cited by 23
Bariatric surgery and T2DM improvement mechanisms: a mathematical model
Toghaw, P., Matone, A., Lenbury, Y., & Gaetano, A. D. (2012) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-9-16 · Cited by 23
Kushwaha, R. N., Srivastava, R., Mishra, A., Rawat, A., Srivastava, A. K., Haq, W., & Katti, S. B. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12426 · Cited by 23
Omarigliptin for the treatment of type 2 diabetes mellitus
Evans, P. M. S., & Bain, S. C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218472 · Cited by 23
Albiglutide: a unique GLP-1 receptor agonist
Rendell, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 24
Landersdorfer, C. B., He, Y., & Jusko, W. J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04109.x · Cited by 23
Chowdhury, S., Wang, S., Patterson, B. W., Reeds, D. N., & Wice, B. M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.10.003 · Cited by 23
Chi, Y., Zhang, H., Huang, W., Zhou, J., Zhou, Y., Qian, H., & Ni, S. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.019 · Cited by 23
Effects of glucagon-like peptide-I on glucose turnover in rats
van Dijk, G., LINDSKOG, S., Holst, J. J., Steffens, A. B., & Åhrén, B. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.6.e1015 · Cited by 22
Self-citationAminomethylpyridines as DPP-IV inhibitors
Peters, J., Weber, S., Kritter, S., Weiss, P., Wallier, A., Zimmerli, D., Boehringer, M., Steger, M., & Loeffler, B. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.049 · Cited by 23
Hulin, B. (1994) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70018-3 · Cited by 23
Kruszynska, Y. T., Ghatei, M. A., Bloom, S. R., & McIntyre, N. (1995) · Hepatology · doi:10.1002/hep.1840210408 · Cited by 24
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
The required beta cell research for improving treatment of type 2 diabetes
Thorens, B. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12096 · Cited by 23
The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice
Hutch, C. R., Roelofs, K. J., Haller, A. M., Sorrell, J. E., Leix, K., D’Alessio, D. D., Augustin, R., Seeley, R. J., Klein, T., & Sandoval, D. A. (2019) · Diabetologia · doi:10.1007/s00125-019-4963-5 · Cited by 22
Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus
Nasr, N. E., & Sadek, K. M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-18534-2 · Cited by 27
Impact of glucagon‐like peptide‐1 on endothelial function
Sjöholm, Å. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01074.x · Cited by 22
Gatford, K. L., Sulaiman, S. A., Mohammad, S. N. B., Blasio, M. J. D., Harland, M. L., Simmons, R. A., & Owens, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056553 · Cited by 22
Ceriello, A., Novials, A., Ortega, E., Canivell, S., Pujadas, G., Sala, L. L., Bucciarelli, L. G., Rondinelli, M., & Genovese, S. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-97 · Cited by 22
Millar, P., Pathak, V., Moffett, R. C., Pathak, N., Bjourson, A. J., O’Kane, M., Flatt, P. R., & Gault, V. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.019 · Cited by 22
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
